The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Testosterone is the only compound in this book where the risk-benefit calculation depends entirely on one number: your baseline serum testosterone level. The same compound, the same dose, the same formulation — appropriate medical treatment in a hypogonadal man; Schedule III misuse in a eugonadal man.
Every other compound in this book is either approved for a specific condition (semaglutide, tirzepatide, tesamorelin) or a research chemical without regulatory classification. Testosterone occupies a unique position: it is simultaneously one of the most important medical treatments in endocrinology and the foundation compound for every androgen-based performance enhancement protocol that has driven decades of regulatory control, sports doping, and community harm. Understanding testosterone requires holding both of these realities simultaneously — not letting the performance use history delegitimize the medical use, and not letting the medical use legitimize performance use.
The chapter is organized accordingly. The medical TRT context — diagnosis, evidence, monitoring, formulations — is presented with the same rigor as any FDA-approved pharmaceutical. The performance use context — supraphysiological dosing in eugonadal men — is presented with equal honesty about what the evidence shows and what it does not. The community that reads this book includes both hypogonadal men seeking to understand their treatment and eugonadal men considering performance enhancement. Both deserve accurate information, not a chapter shaped by either promotional or prohibitionist bias.
THE CENTRAL TENSION
Testosterone deficiency is genuinely associated with increased cardiovascular risk, metabolic syndrome, cognitive decline, reduced bone density, reduced quality of life, and anemia — and TRT in confirmed hypogonadal men addresses all of these outcomes with Grade A evidence (TTrials, NEJM 2016; TRAVERSE, NEJM 2023). At the same time: supraphysiological testosterone in eugonadal men produces dose-dependent adverse effects — erythrocytosis, left ventricular hypertrophy, dyslipidemia (HDL reduction), prostate stimulation, HPTA suppression, testicular atrophy, infertility, and in some contexts cardiovascular harm. The divide between these two clinical contexts is not arbitrary — it is pharmacologically meaningful. Testosterone restoring a deficient man to normal levels is metabolically distinct from testosterone elevating a normal man to supraphysiological levels. This chapter treats these as distinct pharmacological situations requiring distinct evidence-based discussions.
The most common clinical concern for men starting TRT — particularly younger men — is fertility. TRT is not a contraceptive, but it reliably impairs spermatogenesis.
The intratesticular testosterone requirement: spermatogenesis requires intratesticular testosterone concentrations 10-100 times higher than serum levels. Leydig cells produce this concentration locally under LH stimulation. When exogenous testosterone suppresses LH to near-zero, intratesticular testosterone collapses — even if serum testosterone is normal or high. Sperm production falls substantially within weeks and becomes negligible within months in most men. This effect is dose-dependent and essentially universal.
The recovery question: spermatogenesis generally recovers after stopping TRT, but recovery time varies significantly. Published data suggests: within 6 months of stopping, 67% of men recover to baseline sperm concentrations; within 12 months, approximately 90% recover. However, recovery is not guaranteed — longer duration of TRT, higher doses, older age, and pre-existing subfertility are associated with slower or incomplete recovery. For men who want biological children after TRT, stopping TRT 6-12 months before attempting conception is the standard recommendation.
For men on TRT who wish to maintain testicular function and fertility simultaneously, two main approaches are used: (1) HCG (Human Chorionic Gonadotropin): HCG binds the LH receptor on Leydig cells and stimulates intratesticular testosterone production — maintaining spermatogenesis and testicular volume despite HPTA suppression. Typical protocol: 250-500 IU SubQ every other day or 1,000-1,500 IU twice weekly. HCG maintains testicular size, prevents testicular atrophy, and preserves sperm count in the majority of men on TRT. (2) Gonadorelin (GnRH, pulsatile): the physiological signal that drives LH and FSH release; pulsatile administration maintains the full HPTA axis including LH, FSH, and consequently spermatogenesis. Used less commonly than HCG but increasingly popular in functional medicine and progressive TRT practices. (3) Natesto nasal gel: the unique pulsatile pharmacokinetics of Natesto's 3x/daily nasal application have been shown to maintain LH and FSH pulsatility better than other TRT formulations — with preserved spermatogenesis in clinical studies. Option for men who prioritize fertility alongside testosterone optimization.
THE FERTILITY CONVERSATION IS MANDATORY BEFORE STARTING TRT
Any man of reproductive age starting TRT should explicitly discuss fertility with their prescribing physician and document the conversation. 'I might want children someday' is sufficient to warrant a fertility preservation discussion. Options include: sperm banking before starting TRT (the most reliable preservation approach); using HCG or gonadorelin co-administration; using Natesto nasal gel; or deferring TRT until family is complete. The HPTA suppression from TRT is not permanent and not always fully reversible on a predictable timeline. The decision to start TRT at age 28 has different fertility implications than starting at age 52. This is not a reason to avoid TRT when it is clinically indicated — it is a reason to plan.
Testosterone exerts its effects primarily through the intracellular androgen receptor (AR), a member of the nuclear receptor superfamily. The sequence of events: testosterone crosses cell membranes by passive diffusion (as a lipophilic steroid); inside the cell, it binds the AR in the cytoplasm; the testosterone-AR complex undergoes a conformational change and dissociates from heat shock proteins; the active complex dimerizes and translocates to the nucleus; in the nucleus, it binds androgen response elements (AREs) in the promoter regions of androgen-responsive genes; and regulates gene expression — upregulating and downregulating hundreds of targets. The broad effects: anabolic (protein synthesis, muscle growth, bone density); androgenic (secondary sex characteristic development, sebaceous gland activity, hair follicle effects); erythropoietic (EPO production, hemoglobin synthesis — directly relevant to erythrocytosis monitoring); CNS (mood, libido, cognition, aggression at supraphysiological doses); reproductive (spermatogenesis via intratesticular testosterone — paradoxically, exogenous testosterone suppresses spermatogenesis by reducing intratesticular levels via HPTA suppression).
Approximately 5% of testosterone is converted to dihydrotestosterone (DHT) by 5-alpha reductase (5AR) enzymes, primarily in the prostate, skin, and hair follicles. DHT has 3-5x greater binding affinity for the AR than testosterone and is responsible for: prostate growth (clinically relevant for BPH and prostate cancer monitoring during TRT); androgenic alopecia (male pattern baldness in genetically susceptible individuals — the primary DHT-driven cosmetic concern on TRT); some skin oiliness/acne effects. 5-alpha reductase inhibitors (finasteride, dutasteride) reduce DHT conversion and are used adjunctively in TRT protocols by some men experiencing excessive DHT-related effects.
Approximately 0.3% of total testosterone is converted to estradiol (E2) by CYP19A1 aromatase, primarily in adipose tissue, liver, and brain. This is not a side effect to be eliminated — estradiol serves essential physiological functions in men: bone density maintenance (low E2 = bone loss); sexual function (libido requires adequate E2, not just testosterone); mood and cognition; cardiovascular health; protection against some metabolic adverse effects of androgens. The clinical problem arises when TRT drives E2 too high (typically above 40-50 pg/mL): water retention; gynecomastia (breast tissue development — driven by high E2 relative to testosterone); mood disturbance (depression, emotional lability). Aromatase inhibitors (anastrozole, exemestane) are sometimes used to manage high E2 on TRT. The critical balance: over-suppression of E2 (below 20 pg/mL) is as clinically problematic as over-elevation. E2 management on TRT requires measuring E2 (ideally the sensitive LC-MS/MS assay, not standard immunoassay which is less accurate in men) and targeting 20-40 pg/mL.
The hypothalamic-pituitary-testicular axis (HPTA) operates on a negative feedback principle: testosterone and estradiol inhibit GnRH release from the hypothalamus and LH/FSH release from the pituitary. When exogenous testosterone is administered, even at physiological replacement doses, LH and FSH are suppressed within days to weeks. The consequences of LH/FSH suppression: (1) Intratesticular testosterone drops to near-zero (testes produce testosterone only under LH stimulation); (2) Spermatogenesis is suppressed (requires intratesticular testosterone concentrations 10-100x serum levels); (3) Testicular atrophy — the testes shrink from lack of LH stimulation; (4) Fertility is significantly impaired during TRT. Managing HPTA suppression: HCG (human chorionic gonadotropin) mimics LH at the LH receptor and maintains intratesticular testosterone, preserving spermatogenesis and testicular size during TRT; gonadorelin (GnRH, pulsatile) maintains the full HPTA axis. These are commonly co-administered with TRT in men wishing to preserve fertility.
TRT for confirmed hypogonadism has two landmark human evidence pillars: the TTrials (efficacy) and TRAVERSE (cardiovascular safety). Together they establish Grade A evidence for TRT's benefits and safety in appropriately selected hypogonadal men.
Snyder PJ, et al. (2016). Testosterone Treatment in Older Men. NEJM. 374(7):611-624. The TTrials (Testosterone Trials): 7 parallel, placebo-controlled, double-blind RCTs, all conducted simultaneously in the same n=790 men (≥65 years; total testosterone <275 ng/dL; symptomatic hypogonadism); testosterone gel 1% vs placebo gel for 1 year. PRIMARY RESULTS by sub-trial: Sexual function trial: significant improvement in sexual activity, sexual desire, and erectile function (p=0.006). Bone trial: significant increase in lumbar spine and hip bone density (p<0.001) — the most robust bone density improvement of any single intervention in elderly men at the time. Physical function trial: improved walking distance vs placebo; did not meet pre-specified threshold. Vitality trial: improved sexual desire but not overall vitality/fatigue. Anemia trial: testosterone significantly improved hemoglobin in men with unexplained anemia. Cognitive function trial: no significant improvement in memory or cognitive function. Cardiovascular sub-trial: showed increase in non-calcified coronary plaque volume in testosterone group — the most concerning finding, though clinical significance is debated (non-calcified plaque ≠ calcified plaque ≠ MACE). The TTrials established Grade A evidence for TRT benefits in sexual function, bone density, and anemia in hypogonadal elderly men.
Lincoff AM, Bhasin S, et al. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. NEJM. 389(2):107-117. The FDA-mandated cardiovascular outcomes trial. Design: Phase 4, randomized, double-blind, placebo-controlled, noninferiority, event-driven; n=5,246 men; age 45-80; documented hypogonadism (Total T <300 ng/dL x2 AM); preexisting CVD or high CV risk; testosterone 1.62% transdermal gel vs placebo; median follow-up 33 months. PRIMARY ENDPOINT: MACE (cardiovascular death, nonfatal MI, nonfatal stroke). RESULT: MACE occurred in 7.0% of testosterone group vs 7.3% of placebo group (HR 0.96; 95% CI 0.78-1.17); pre-specified noninferiority margin met (upper bound of CI <1.50). Conclusion: TRT is NOT associated with increased MACE in hypogonadal men. SECONDARY SAFETY: higher rates of pulmonary embolism, atrial fibrillation, and acute kidney injury in testosterone group (statistically significant but absolute differences small). No increase in prostate cancer incidence. This trial settled a decade-long cardiovascular controversy. The Androgen Society position paper (Mayo Clinic Proceedings, 2024) characterizes TRAVERSE as 'a watershed moment providing definitive evidence that TTh is not associated with increased MACE.'
Outcome
Grade
Key Evidence
Notes
Sexual function improvement (hypogonadal men)
A
TTrials Sexual Function sub-trial (NEJM 2016): significant (p=0.006); n=790
Applicable to confirmed hypogonadal men only; not eugonadal
Bone density improvement
A
TTrials Bone sub-trial (NEJM 2016): significant lumbar spine + hip (p<0.001)
Strongest bone density evidence of any single intervention in elderly men at time
Anemia improvement
A
TTrials Anemia sub-trial: significant hemoglobin improvement in unexplained anemia
Relevant for hypogonadal men with anemia
Cardiovascular safety (MACE)
A — non-inferiority
TRAVERSE (NEJM 2023): HR 0.96; non-inferiority confirmed in n=5,246 men with CVD risk
Confirms safety in high-risk hypogonadal men at physiological TRT doses
Non-calcified coronary plaque
Caution signal
TTrials cardiovascular sub-trial: increased non-calcified plaque in TRT group
Clinical significance debated; TRAVERSE showed no MACE increase despite this finding
Fatigue/vitality
B — mixed
TTrials Vitality sub-trial: improved sexual desire but not overall vitality
Inconsistent with patient-reported experience; trial design limitations noted
Cognitive function
C — negative
TTrials Cognitive sub-trial: no significant improvement
Memory function not improved in TTrials; some later studies suggest benefit in younger men
Mood and depression
B
Multiple RCTs; meta-analyses show modest improvement in mood and depression symptoms
Not reflected in TTrials (not a primary endpoint) but consistent in later trials
The most important clinical decision in TRT beyond diagnosis is formulation selection — each route has distinct pharmacokinetics, administration burden, and practical considerations.
Formulation
Half-life
Typical Dosing
Peaks/Troughs
Practical Notes
Testosterone Cypionate (IM/SubQ)
~8 days
50-100 mg IM/SubQ weekly (or split twice weekly)
Moderate peaks and troughs with weekly; split dosing more stable
Most common in US; SubQ preferred by many for less discomfort; cypionate and enanthate nearly interchangeable
Testosterone Enanthate (IM/SubQ)
~5 days
50-100 mg IM/SubQ every 5-7 days
Slightly faster fall than cypionate; weekly usually adequate
Slightly shorter t1/2; equivalent clinical profile; both cypionate and enanthate standard TRT options
Testosterone Propionate (IM)
~2 days
25-50 mg IM every 2-3 days
Higher peaks, faster clearance; more frequent injections
More frequent dosing burden; used in some protocols for rapid level adjustment; more commonly used in performance context
Testosterone Undecanoate IM (Aveed)
~34 days
750 mg IM at 0, 4 weeks, then every 10 weeks
Very stable levels; slow clearance
Clinic-administered; FDA REMS requirement; rare serious pulmonary reactions; excellent adherence advantage
Testosterone Undecanoate oral (Jatenzo)
Hours (oral)
158-237 mg twice daily with food
Multiple daily peaks; must be taken with fat-containing meal
Avoids hepatic first-pass via lymphatic absorption; expensive; less popular than injectable
Testosterone Gel 1% / 1.62% (topical)
Continuous from skin
50-81 mg/day applied to skin
Stable levels without injection peaks/troughs
Transfer to partner/children is the primary concern; consistent daily application required; TRAVERSE trial formulation
Testosterone Cream (compounded)
Continuous from skin
Variable; typically 10-20% cream on scrotum
Scrotal absorption significantly higher than other skin sites
High scrotal absorption due to thin skin and high vascularity; significant DHT conversion from scrotal application; not FDA-approved (compounded)
Testosterone Pellets (subcutaneous)
60-90 days
150-900 mg pellets implanted by physician
Very stable levels; no daily or weekly burden
3-6 month intervals; minor surgical procedure; popular in specialty longevity clinics; dose harder to adjust than injectable
Testosterone Nasal Gel (Natesto)
Hours
11 mg intranasal 3x/day
Multiple daily peaks; frequent dosing
Maintains LH/FSH pulsatility better than other routes (unique advantage for fertility preservation); complex 3x/daily burden
Test
When
Target/Action
Why
Total testosterone (trough)
3 months, 6 months, then annually; trough = just before next injection
400-700 ng/dL mid-cycle trough
Confirms adequate replacement; too low = increase dose; too high = reduce dose or frequency
Hematocrit (Hct)
3 months, 6 months, then annually
<54%; if 54-56% reduce dose or donate blood; if >56% hold TRT
Erythrocytosis is the most common clinically relevant adverse effect of TRT; elevated Hct increases blood viscosity and thrombosis risk
Estradiol (E2)
If symptomatic; or at 3-6 months
Target 20-40 pg/mL (sensitive assay); symptoms guide more than number
Too high: water retention, gynecomastia, mood; too low: bone loss, libido impairment, mood; use sensitive LC-MS/MS assay — standard immunoassay inaccurate in men
PSA (Prostate Specific Antigen)
Baseline; 3-6 months; then annually in men >40
<4 ng/mL standard; >4 or rapid rise >0.4/year = urology referral
TRT stimulates prostate growth; PSA is the primary prostate cancer screening tool; TRT is contraindicated in men with active or suspected prostate cancer
LH / FSH
Baseline; optionally at follow-up
Suppressed on TRT (expected); checking confirms exogenous androgen use
Confirms HPTA suppression; LH/FSH near-zero on TRT is expected and normal
SHBG (Sex Hormone Binding Globulin)
Baseline; optional follow-up
Provides context for free testosterone interpretation
High SHBG = low free T despite normal total T; low SHBG (common in obesity/T2D) = high free T relative to total T
Lipid panel
Baseline; 6 months; annually
Standard cardiovascular risk management
Testosterone mildly reduces HDL (dose-dependent); LDL/TC effects variable; lipid monitoring standard of care
CBC (hematocrit/hemoglobin)
Same as hematocrit above
As above
Erythrocytosis monitoring
Testicular size
Clinical exam baseline and follow-up
Monitoring for atrophy; HCG use decision
Testicular atrophy is expected on TRT without HCG; some men find this cosmetically or psychologically significant
Testosterone stimulates EPO production by the kidneys and directly stimulates erythroid progenitor cells, increasing red blood cell mass. This produces erythrocytosis — elevated hematocrit and hemoglobin. In TRAVERSE, the rate of clinically significant erythrocytosis (hematocrit >54%) was approximately 5% in the testosterone group vs 1% in placebo. The clinical concern: elevated hematocrit increases blood viscosity, which theoretically increases thrombosis risk (VTE, pulmonary embolism, stroke). In TRAVERSE, pulmonary embolism and atrial fibrillation were more frequent in the testosterone group (absolute differences small). Management: hematocrit monitoring every 3-6 months; if Hct exceeds 54%, reduce dose or frequency; if >56%, hold TRT; therapeutic phlebotomy (donating blood) is sometimes used to manage erythrocytosis. Note: erythrocytosis is dose-dependent — men on performance-level supraphysiological doses have substantially higher rates than men on physiological TRT doses.
Testosterone stimulates prostate growth via the androgen receptor. Active or suspected prostate cancer is an absolute contraindication to TRT. TRT is not clearly established as causing de novo prostate cancer — the saturation model of prostate androgen response suggests that physiological testosterone levels fully saturate the AR, and additional testosterone above the saturation point does not increase prostate cancer risk proportionally. The TTrials and TRAVERSE showed no significant increase in prostate cancer incidence with TRT. PSA monitoring is required during TRT as the primary screening tool. Men with benign prostatic hyperplasia (BPH) may have worsened urinary symptoms on TRT. Men with a history of treated prostate cancer are generally considered candidates for TRT only after discussion with their urologist — this is evolving based on emerging data suggesting TRT safety in appropriately selected prostate cancer survivors.
TRAVERSE established cardiovascular safety (no increased MACE) for TRT in hypogonadal men at physiological replacement doses. The nuances: (1) The TTrials cardiovascular sub-study showed increased non-calcified coronary plaque volume — this was a surrogate marker and did not translate to increased MACE in TRAVERSE; (2) TRAVERSE showed small but statistically significant increases in pulmonary embolism and atrial fibrillation; (3) All cardiovascular safety data applies to physiological TRT doses — it does NOT establish cardiovascular safety of supraphysiological testosterone use; (4) Left ventricular hypertrophy (LVH) is documented with supraphysiological androgen use and is not addressed by TRAVERSE which used physiological doses.
Testosterone mildly reduces HDL cholesterol (dose-dependent; typically 5-15% reduction on standard TRT doses; greater reduction with supraphysiological doses). LDL and total cholesterol effects are variable and less consistent. The net cardiovascular lipid effect appears modest at physiological doses and is outweighed by the other cardiovascular benefits of correcting hypogonadism. At supraphysiological doses, the HDL reduction is more pronounced and contributes meaningfully to cardiovascular risk.
TRAVERSE and TTrials apply to physiological testosterone replacement in confirmed hypogonadal men. The body of evidence for supraphysiological testosterone use in eugonadal men — which characterizes the performance enhancement context — is different in character: smaller studies, higher adverse event rates, higher doses, different population. The Basaria et al. 2010 NEJM paper (the testosterone in older men with mobility limitations trial) was stopped early due to increased cardiovascular events in the testosterone group — at doses that produced supraphysiological levels in some participants. This illustrates that the safety established by TRAVERSE is specific to physiological TRT, not to all androgen use.
The same compound. Different population. Different dose. Categorically different risk-benefit profile.
Parameter
TRT in Confirmed Hypogonadism
Performance Enhancement (Eugonadal Men)
Indication
Confirmed testosterone deficiency (<300 ng/dL x2) + symptoms
Desire for supraphysiological testosterone levels
Baseline testosterone
Low (300 ng/dL or below)
Normal (typically 400-700 ng/dL or higher)
Target testosterone
Mid-normal range (400-700 ng/dL at trough)
Supraphysiological (often 1,000-5,000+ ng/dL)
Cardiovascular risk
TRAVERSE: no increased MACE; physiological doses
Supraphysiological doses: LVH, erythrocytosis, dyslipidemia, increased thrombosis risk
HPTA recovery after stopping
Generally recover to baseline levels (may be slow)
May have prolonged recovery; permanent suppression possible with long-term supraphysiological use
Prostate safety
PSA monitoring; no increased cancer incidence (TTrials, TRAVERSE)
Dose-dependent prostate stimulation; higher risk with supraphysiological doses
Erythrocytosis
~5% at physiological doses (TRAVERSE)
Substantially higher rates with supraphysiological doses
Regulatory status
FDA-approved; legal with prescription; Schedule III controlled substance
Schedule III controlled substance; possession without prescription = federal crime (US)
WADA status
Therapeutic Use Exemption (TUE) required for athletic competition
Banned S1 (no TUE without confirmed clinical hypogonadism)
Fertility impact
Same — HCG/gonadorelin co-administration available; recovery after stopping
Same pharmacology; potentially longer recovery with long-term supraphysiological use
No topic in TRT generates more community confusion than estradiol. The standard community framing — 'E2 is the enemy; crash it with anastrozole' — is pharmacologically incorrect and causes significant clinical harm.
The physiological reality: estradiol (E2) is not a side effect of testosterone therapy — it is a hormone that serves essential functions in men, including bone density maintenance, sexual function (libido requires adequate E2 not just testosterone), mood stabilization, cardiovascular protection, and cognitive function. Men with naturally low estradiol have worse bone density, worse sexual function, and worse mood than men with adequate estradiol — regardless of testosterone levels. Estradiol is not the enemy.
The problem is not estradiol per se; it is excess estradiol relative to testosterone producing symptom burden (water retention, gynecomastia, mood instability). The therapeutic goal is balance: testosterone in the mid-normal range AND estradiol in the 20-40 pg/mL range. Crashing E2 with aggressive aromatase inhibitor use produces the classical low-E2 syndrome: joint pain, bone loss, sexual dysfunction, depression, and cognitive impairment — symptoms that are often misattributed to 'still too low testosterone' leading to further dose increases in a clinically counterproductive spiral.
When to consider aromatase inhibitor use: only when estradiol is genuinely elevated (>50 pg/mL on sensitive assay) AND the patient is symptomatic (gynecomastia, significant water retention, documented mood instability from E2 excess). The first-line intervention for elevated E2 on TRT is usually dose reduction or increased injection frequency (reducing peak testosterone and therefore peak aromatization) — not AI use. Many TRT practitioners advocate AI-free protocols entirely, managing E2 through dose optimization rather than pharmacological inhibition.
THE ASSAY MATTERS — USE SENSITIVE E2 TESTING
Standard immunoassay estradiol tests (the most commonly ordered in clinical labs) are designed for women and use antibodies optimized for the high-E2 range of the female menstrual cycle. In men, where E2 runs much lower, these assays are notoriously inaccurate — frequently overreporting E2 by 20-50%. Men pursuing TRT should request the 'sensitive' or 'ultrasensitive' estradiol assay (LC-MS/MS liquid chromatography-mass spectrometry), also called 'estradiol, sensitive' or 'estradiol, ultrasensitive' on lab order forms. A 'high' E2 on standard immunoassay in a man on TRT may be entirely normal on sensitive assay. Managing AI use based on inaccurate standard assay results is a common source of iatrogenic harm in community TRT.
Testosterone is on the WADA Prohibited List as S1.1 (Anabolic Androgenic Steroids) — a prohibited substance in competition and out-of-competition. This is an absolute ban. Detection methodology: WADA uses the T/E ratio (testosterone to epitestosterone ratio; normally ~1:1; flagged above 4:1) as an initial screen; Carbon Isotope Ratio (CIR) testing can distinguish synthetic from endogenous testosterone even at T/E ratios within normal limits (endogenous testosterone has naturally occurring carbon-13 enrichment that synthetic testosterone lacks). This means an athlete who uses pharmaceutical-grade testosterone — even at TRT doses — will have different isotope ratios from endogenous production and can be detected by CIR testing regardless of T/E ratio. Therapeutic Use Exemptions (TUEs) are available for athletes with confirmed clinical hypogonadism meeting the criteria — but the TUE process requires documented diagnosis, treatment necessity, and that the treatment restores to normal rather than supraphysiological levels.
US legal status: testosterone is classified as Schedule III under the Controlled Substances Act. Possession without a valid prescription is a federal crime. Prescription is legal only for FDA-approved indications. Prescriptions for performance enhancement in eugonadal men are not a legitimate FDA-approved use. Online 'TRT clinics' prescribing testosterone to men without confirmed laboratory hypogonadism are operating outside the FDA's approved indication, though the legal enforcement complexity in this gray area varies.
TRT in confirmed hypogonadal men restores testosterone to normal physiological levels (400-700 ng/dL target). Performance enhancement involves supraphysiological testosterone levels (often 1,000-5,000+ ng/dL). These are pharmacologically distinct: physiological restoration of a deficient hormone; vs. pharmacologically elevating a normal hormone to unnaturally high levels. The cardiovascular, metabolic, and prostate safety profiles are fundamentally different between these two contexts. TRAVERSE's safety findings apply to TRT — not to performance-level androgen use.
Estradiol serves essential physiological functions in men including bone density, sexual function, mood, and cardiovascular protection. Routine E2 suppression with aromatase inhibitors in the absence of documented symptomatic E2 excess (gynecomastia, significant water retention, E2 >50 pg/mL on sensitive assay) is inappropriate and causes clinical harm. The target is E2 balance (20-40 pg/mL), not suppression. Use sensitive LC-MS/MS assay — standard immunoassay is inaccurate in men.
TRAVERSE (n=5,246; median 33-month follow-up) showed no increase in MACE from TRT in confirmed hypogonadal men. Low testosterone itself is associated with increased cardiovascular risk. The net cardiovascular effect of correcting hypogonadism with physiological TRT is neutral-to-beneficial based on the current evidence. The cardiovascular risks that do exist with TRT (erythrocytosis, small increase in pulmonary embolism in TRAVERSE) are specific, measurable, and manageable with monitoring. This does not apply to supraphysiological testosterone use.
A single total testosterone level below 300 ng/dL is not diagnostic of hypogonadism requiring treatment. Diagnosis requires: (1) Two morning measurements below 300 ng/dL on separate days; (2) Presence of specific clinical symptoms; (3) Exclusion of secondary causes (pituitary pathology, sleep apnea, obesity, medications). Total testosterone also varies with time of day, illness, weight changes, and stress. One low value is insufficient for diagnosis or treatment initiation.
Snyder PJ, et al. (2016). Testosterone Treatment in Older Men. New England Journal of Medicine. 374:611-624. [7 parallel RCTs; n=790; ≥65 hypogonadal men; 1 year testosterone gel vs placebo; significant improvement: sexual function (p=0.006), bone density (p<0.001), anemia; foundational efficacy evidence for TRT in older men.]
Lincoff AM, Bhasin S, et al. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 389(2):107-117. [Phase 4 DBRPC; n=5,246; age 45-80; preexisting/high CV risk hypogonadal men; 33-month median follow-up; HR 0.96 for MACE; non-inferiority confirmed; the definitive cardiovascular safety trial for TRT.]
Androgen Society. (2024). Position Paper on Cardiovascular Risk With Testosterone Therapy. Mayo Clinic Proceedings. October 2024. [Post-TRAVERSE expert position; characterizes TRAVERSE as watershed moment; confirms TRT not associated with increased MACE when used as indicated.]
Wenker EP, Dupree JM, Langille GM, et al. (2015). The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. Journal of Sexual Medicine. 12(6):1334-1337. [HCG protocol for spermatogenesis recovery; the primary evidence base for HCG co-administration with TRT for fertility preservation.]
TRT for confirmed hypogonadism is one of the most evidence-based medical interventions in endocrinology. The risk-benefit calculation depends entirely on whether hypogonadism is confirmed — and on keeping the dose physiological.
The honest summary: testosterone deficiency is a real, measurable condition with documented downstream consequences for quality of life, sexual function, bone health, and metabolic health. TRT for confirmed hypogonadism is Grade A evidence-based treatment — TRAVERSE settled the cardiovascular safety question that had been controversial for a decade, TTrials established efficacy across multiple clinically relevant domains. The monitoring protocol is well-defined. The formulation choice is individualized. The E2 balance understanding, while misrepresented in community discourse, is pharmacologically clear. For men with confirmed hypogonadism: TRT is appropriate, evidence-based, and manageable with proper monitoring. For men with normal testosterone seeking performance enhancement or body composition improvement: the risk-benefit calculation is entirely different, the regulatory context is different, the legal context is different, and the TRAVERSE/TTrials evidence does not apply.
— End of Testosterone / TRT —
THE PEPTIDE BIBLE | Testosterone / TRT | For Research & Educational Purposes Only
Testosterone: primary male androgen; 19-carbon steroid; endogenous (Leydig cells 95% in men); FDA-approved multiple formulations; Schedule III controlled substance (US); WADA S1 absolute ban. MECHANISM: AR agonism (nuclear receptor); AR-T complex → nucleus → androgen response elements → gene regulation; anabolic (protein synthesis, muscle, bone), androgenic (secondary sex characteristics, sebaceous, hair), erythropoietic (EPO, hemoglobin), CNS (mood, libido, cognition). DHT: 5% converted by 5AR → 3-5x AR affinity → prostate, skin, hair follicles. AROMATIZATION: ~0.3% → estradiol via CYP19A1; E2 is essential (bone density, sexual function, mood, cardiovascular) — not optional to suppress; target E2 20-40 pg/mL (sensitive LC-MS/MS assay); over-suppression with AI = clinical harm. HPTA SUPPRESSION: exogenous T → LH/FSH suppressed → intratesticular T drops → spermatogenesis suppressed → testicular atrophy; HCG (250-500 IU EOD) or gonadorelin preserves fertility and testicular function during TRT. HYPOGONADISM DIAGNOSIS: Total T <300 ng/dL x2 (AM blood draws, separate days) + specific symptoms (reduced libido, ED, fatigue, depressed mood, reduced lean mass, hot flushes, osteoporosis, anemia). Both criteria required. TTRIALS (NEJM 2016; Snyder; n=790; ≥65yo; 7 parallel DBRPC RCTs; 1 year): sexual function ↑ (p=0.006); bone density ↑ (p<0.001); anemia ↑; vitality mixed; cognitive function neutral; CV sub-study: increased non-calcified plaque (clinical significance debated). TRAVERSE (NEJM June 2023; Lincoff/Bhasin; n=5,246; age 45-80; preexisting/high CV risk; 33-month follow-up): MACE HR 0.96 (CI 0.78-1.17); non-inferiority confirmed; TRT does NOT increase MACE. Small increases in PE and AF in TRT group (absolute differences small). The definitive CV safety trial. FORMULATIONS: Cypionate (t1/2 8d; weekly SubQ/IM); Enanthate (t1/2 5d; q5-7d); Propionate (t1/2 2d; q2-3d); Undecanoate IM (Aveed; 10-weekly); Undecanoate oral (Jatenzo); Gel 1%/1.62%; Cream (compounded); Pellets (3-6 months); Natesto nasal (TID; best fertility preservation of any route). MONITORING: Testosterone trough (target 400-700 ng/dL); Hct (hold if >54%); PSA; E2 (sensitive assay if symptomatic); LH/FSH; SHBG; lipids; testicular exam. CONTRAINDICATIONS: active/suspected prostate cancer (absolute); male breast cancer (absolute); polycythemia; severe sleep apnea; HF exacerbation risk; near-term fertility without HCG planning. TRT vs PERFORMANCE: physiological TRT (confirmed hypogonadal, target 400-700 ng/dL) ≠ performance enhancement (eugonadal, target 1000-5000+ ng/dL); TRAVERSE safety does NOT apply to supraphysiological use; different risk-benefit profile entirely. WADA: S1 absolute ban; T/E ratio >4:1 + CIR testing; TUE available for confirmed hypogonadism.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.